CUE (Cue Biopharma Inc.) Enterprise Value-to-Sales Ratio

Public company logo of Cue Biopharma, Inc. (CUE)

Cue Biopharma, Inc. (CUE) is deploying reserves toward costly R&D focused on T-cell control. The development of Immuno-STAT targets the global immuno-oncology market by mimicking natural signals. The company's current price-to-sales valuation confirms the asset's dynamics, where -313.97 is recorded as the baseline value. However, uncertainty regarding partner payments and a capital deficit prior to commercialization create significant risks for investors.

CUE (Cue Biopharma Inc.) EV/Sales Multiple history from 11/23/2025 to 11/20/2026

CUE (Cue Biopharma, Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Fundamental company valuation:CUE - cuebiopharma.com
Core merchandise of Cue Biopharma Inc.

To minimize the risk of overpaying for an asset, it is necessary to analyze the Enterprise Value to Revenue (EV/Revenue) ratio, which strips the valuation of the impact of debt load. On the GURU.Markets platform, the EV/Sales multiple allows for a comparison of Cue Biopharma, Inc. (CUE) market capitalization against its actual revenues, which is critically important for a non-cyclical, pre-revenue biopharmaceutical business that is completely isolated from macroeconomic shocks and inflation.

Competitor analysis

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP